Guidelines

FDA increases transparency of biosimilar applications

Home/Guidelines | Posted 22/01/2021

The US Food and Drug Administration (FDA) has made changes to the review of its Biologics License Applications (BLAs) in order to improve transparency and communication.

US guidance on proprietary names

Home/Guidelines | Posted 15/01/2021

The US Food and Drug Administration (FDA) issued a guidance for industry on best practices in developing proprietary names for prescription drugs, in December 2020 [1].

Biosimilar User Fee Act reauthorization

Home/Guidelines | Posted 11/12/2020

The US Food and Drug Administration (FDA) Biosimilar User Fee Act (BsUFA) is due to be reauthorized for the second time (BsUFA III) in 2022. BsUFA allows FDA to collect fees from companies that are developing biosimilar and interchangeable products.

FDA issues Q & A on biosimilars

Home/Guidelines | Posted 04/12/2020

The US Food and Drug Administration (FDA) issued draft Questions and Answers (Q & A) on biosimilars development and the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) in November 2020.

FDA new and revised guidances for complex generics

Home/Guidelines | Posted 27/11/2020

The US Food and Drug Administration (FDA) has announced new and revised product-specific guidances to support the development and approval of safe and effective complex generic drug products.

UK releases post-Brexit biosimilar guidelines

Home/Guidelines | Posted 06/11/2020

The UK has left the European Union (EU) and the exit transition period ends in January 2021. At this point, the regulation of medicines and devices will be transferred to the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This move away from EU regulation will involve some significant changes.

FDA’s new MAPP explains route for changing ownership of generic drug applications

Home/Guidelines | Posted 25/09/2020

The US Food and Drug Administration (FDA) recently issued a new Manual of Policies and Procedures (MAPP) which outlines how the Office of Generic Drugs (OGD) will process requests to transfer ownership of generic drug applications, and how it will update the Orange Book to reflect those changes.